XTL Biopharmaceuticals Ltd. (TLV: XTLB)

Market Cap	63.97M
Revenue (ttm)	n/a
Net Income (ttm)	-1.40M
Shares Out	1.25B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,735,223
Open	5.10
Previous Close	5.10
Day's Range	5.10 - 6.30
52-Week Range	0.03 - 6.30
Beta	0.88
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 26, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: XTLB

Financial Performance

Financial numbers in USD